Treasury Wine shares: turnaround or trap?

Treasury Wine Estates Ltd (ASX: TWE) investors have been strapped into quite the roller coaster. And the ride isn’t over yet.

After a brutal plunge over the past year, Treasury Wine shares have staged a sharp comeback. The ASX wine stock kicked off the new week around 4% higher at $5.36, pushing its six-month gain to roughly 50%.

Impressive stuff, until you zoom out. Over the past 12 months, Treasury Wine shares are still down about 28%.

So which is it: genuine turnaround, or a rebound that’s got ahead of itself?

A radical reset or a radical gamble?

The company’s June strategy reset is doing a lot of heavy lifting here. Treasury Wine is ripping up its old playbook, slashing its brand count from 76 down to fewer than 30 over five years and throwing its weight behind flagship label Penfolds.

The troubled Americas business is under review, and management is chasing roughly $100 million in annualised cost savings by FY29.

The stated goal: fatter margins, a simpler business, and capital funneled toward the brands that can actually move the needle. Treasury Wine is now targeting a long-term EBITS margin above 25%.

The market went wild for it, shares have jumped more than 25% since the day the reset strategy dropped. But strip away the enthusiasm, and there’s a much less comfortable story underneath.

Not so fast, this isn’t a turnaround yet

A share-price rally doesn’t magically erase the problems that caused the crash in the first place. Treasury Wine has already booked a further $558.4 million post-tax non-cash impairment on its US assets — a brutal reminder of just how badly the Americas business has gone off the rails.

FY27 is shaping up as a transition year for Treasury Wine shares, not a victory lap. The entire bull case hinges on management nailing a portfolio overhaul, fixing bloated inventory, actually banking those promised cost savings, and keeping Penfolds growing through it all.

That’s a lot of moving parts, and a lot can still go wrong. The uncomfortable read is that the recent rebound might just be the market getting ahead of itself, pricing in a turnaround before any of those benefits have actually shown up in the numbers.

What do the brokers think?

Analysts are warming up to Treasury Wine shares, but nobody’s fully sold. Morgans has a buy rating and a $7.30 target, recently lifted from $5.95. That suggests a 36% upside from current price levels.

Citi is bullish too, with a buy rating and $6.95 target. UBS sits more cautiously at hold with $6.50, and JPMorgan mirrors that with a $6.00 hold.

Across 16 analysts, the average target lands around $6.25, 17% above Treasury Wine’s current $5.36 price. On paper, that’s real upside if the transformation actually delivers.

Foolish takeaway

After one of the wildest years in Treasury Wine’s history, a 50% six-month rally isn’t proof of anything. It’s a promissory note. Brokers see potential for Treasury Wine shares, but potential and delivery are two very different things.

Until the wine company actually executes on cost cuts, inventory discipline and Penfolds growth, calling this a turnaround might be jumping the gun. Investors watching from the sidelines are right to want to see results before believing the story.

The post Treasury Wine shares: turnaround or trap? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• These are the 10 most shorted ASX shares
• These are the 10 most shorted ASX shares
• What are the most shorted ASX shares on the market right now?
• These are the 10 most shorted ASX shares

JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.